Objective: This study aims to evaluate the effect of operator experience on the treatment outcomes of radiofrequency ablation (RFA) for malignant liver tumors. Summary Background Data: RFA is gaining popularity as the ablative therapy of choice for liver tumors. It is generally considered a simple and safe technique, and little attention has been paid to the importance of operator experience in this treatment. A learning curve in this treatment modality has not been documented before.
Objective: This study aims to evaluate the effect of operator experience on the treatment outcomes of radiofrequency ablation (RFA) for malignant liver tumors. Summary Background Data: RFA is gaining popularity as the ablative therapy of choice for liver tumors. It is generally considered a simple and safe technique, and little attention has been paid to the importance of operator experience in this treatment. A learning curve in this treatment modality has not been documented before. Patients and Methods: The clinical data and treatment outcomes of the initial 100 patients undergoing RFA for liver tumors (hepatocellular carcinoma, n ϭ 84; metastasis, n ϭ 15; cholangiocarcinoma n ϭ 1) were collected prospectively. All patients were managed by a single team of surgeons and interventional radiologists. The data of the first 50 patients (group I) and the second 50 patients (group II) were compared. Results: RFA was performed by percutaneous (group I, n ϭ 22; group II, n ϭ 19) , open (group I, n ϭ 26; group II, n ϭ 30) or laparoscopic (group I, n ϭ 2; group II, n ϭ 1) approach. In group I, 30 patients (60%) had a solitary tumor and 20 (40%) had multiple tumors; in group II, 35 patients (70%) had a solitary tumor and 15 (30%) had multiple tumors (P ϭ 0.295). The size of the largest tumor was comparable between groups I and II (median, 2.8 cm in both groups; P ϭ 0.508). Group II had significantly shorter hospital stay (median, 4.0 versus 5.5 days; P ϭ 0.048), lower morbidity rate (4% versus 16%; P ϭ 0.046) and higher complete ablation rate (100% versus 85.7%; P ϭ 0.006) than group I. There was 1 hospital death (2%) in group I and 0 in group II. By multivariate analysis, treatment period (group I versus group II) was an independent significant factor affecting the morbidity rate and complete ablation rate. Conclusions: A low complication rate and a high complete ablation rate could be achieved with the accumulated experience from the first 50 cases of RFA for liver tumors by a specialized team. This study demonstrates that there is a significant learning curve in RFA for liver tumors. R adiofrequency ablation (RFA) is a relatively new and minimally invasive therapy for primary and metastatic liver tumors. Early studies have suggested that this is an effective and safe technique for treating liver tumors. [1] [2] [3] [4] [5] [6] As a result, RFA is gaining popularity as the preferred modality of local ablation for unresectable liver tumors in many centers. 7, 8 With its technical simplicity and safety, RFA has even been proposed as an alternative to hepatic resection for small liver tumors. 4, 9, 10 In view of the current enthusiasm for RFA treatment of liver tumors, many authors have reviewed the safety and efficacy of this treatment based on data from the literature. A recent review of the complications of RFA for liver tumors concluded that the morbidity and mortality of RFA are higher than previously assumed, with an overall complication rate of 8.9% among 3670 patients reported in the literature. 11 In another review, the complete ablation rate of RFA for liver tumors was found to vary widely from 50% to 95% in different reports. 7 Such a wide variation in the results is often attributed to the differences in the probe devices and techniques. As RFA is a technology-based treatment, much attention has been focused on technical improvements of the probes. The importance of operator experience in this treatment was seldom alluded to in previous reports.
Experience from laparoscopic surgery, which is another type of technology-based minimally invasive treatment, has led to the discovery of the importance of a learning curve in new surgical procedures. [12] [13] [14] [15] Such a learning curve is not only confined to laparoscopic surgery but is also intrinsic to many other new health technologies. 16 It is considered an obligation for the clinicians who are starting a new health technology in the treatment of patients to recognize and overcome the associated learning curve. 17 While such a learning curve is also likely to apply to RFA treatment of liver tumors, many clinicians are embarking on this treatment without paying much attention to the learning curve because RFA is often perceived as a simple technique of inserting a needle to "cook" the tumor.
To our knowledge, there have not been any studies that evaluated the effect of operator experience on the treatment outcomes of RFA for liver tumors. Hence, we conducted a prospective study to clarify whether there is a learning curve in RFA for liver tumors when the treatment was initiated in our institution.
PATIENTS AND METHODS
RFA treatment of liver tumors in Queen Mary Hospital, The University of Hong Kong, Hong Kong was initiated in April 2001. To concentrate and strengthen expertise of the treatment and to facilitate research on this new treatment modality, a team comprising 4 hepatobiliary surgeons (Poon, Ng, Lam and Fan) with substantial experience in the management of liver cancers and 2 interventional radiologists (Ai and Yuen) with experience in interventional procedures in the liver was responsible for this treatment in our institution. The surgeons involved had good experience in intraoperative and laparoscopic ultrasonography.
All RFA treatments were performed under a standard protocol using the cool-tip® RF system (Radionics Inc, Burlington, MA). Patients with Յ 3 tumors, each Յ 5 cm in diameter, were considered the favorable candidates for RFA. 7 However, we also offered RFA to selected patients with more than 3 tumor nodules or tumors larger than 5 cm (up to 8 cm) if no other effective treatment options were available and if the liver function was satisfactory. A single electrode with a 2 cm or 3 cm exposed tip was used for tumors smaller than 3 cm in diameter, and a clustered probe consisting of 3 parallel electrodes was used for tumors Ͼ 3 cm in diameter. Ablation was performed with a curative intent, aiming to achieve a margin of 1 cm. Patients with small tumors located in a position amenable to percutaneous RFA were treated with this approach. Open approach was offered in the following situations: (1) large tumors that require multiple ablations even with the clustered probe; (2) tumors located near the dome of the liver, for which percutaneous ablation will cause pneumothorax or damage to the diaphragm; or (3) tumors located near the visceral organs such as the gallblad-der, colon, or stomach. In selected patients without previous upper abdominal operation, laparoscopic approach was used instead of the open approach if the tumor position was favorable. All patients were reviewed by the team before the approach of RFA was decided. Tumor pathology was confirmed by percutaneous fine needle aspiration cytology for patients undergoing percutaneous RFA, and by core-needle biopsy for those undergoing laparoscopic or open RFA. A dose of intravenous antibiotics (Augmentin; Beecham Pharmaceuticals, Brentford, England) was given just before RFA and oral antibiotics was continued for 5 days after treatment.
Percutaneous ablation was performed with ultrasound guidance under local anesthesia by 1 of the 2 interventional radiologists together with a surgical member of the team. In the early period, intravenous sedation using midazolam and meperidine was routinely given before insertion of the needle probe in addition to local anesthesia. However, we often encountered difficulty in accurate placement of the probe in the desired position within the tumors, especially those located in the upper portion of the liver, because the patients could not cooperate in breathing after sedation. In the latter period, needle probe insertion was performed under local anesthesia without sedation or with mild sedation only. The needle puncture was usually well-tolerated by patients, who could cooperate by holding breath transiently to facilitate placement of the probe in the tumors by the radiologist. Full sedation was provided only after the ablation process had been started, which usually caused more pain than the needle puncturing itself. All open or laparoscopic ablations were performed by the surgeons under the guidance of intraoperative or laparoscopic ultrasound. Hepatic vascular inflow occlusion was not applied in any patients.
The ablation was performed using an automatic impedance control mode in which the current output was automatically adjusted according to the impedance at the needle tip. Temperature at the needle tip was also monitored. The needle tip was continuously perfused with cold saline via an internal channel inside the needle throughout the ablation to maintain the temperature below 20°C, thus preventing charring around the needle tip. In our early practice, the duration of each ablation cycle was set at 12 minutes according to the recommendation of the manufacturer of the RFA system. However, in the latter period, a more flexible duration of 6 to 12 minutes for each ablation cycle was adopted, depending on the site and size of the tumor. This was based on our observation that a substantial volume of ablation could be achieved within the first 6 to 8 minutes of ablation, with a less steep rise in the volume of ablation afterward.
To prospectively evaluate the results of the treatment, the clinical data of all patients were prospectively collected in a computerized database. Response to ablation was assessed by a computed tomography (CT) scan 1 month after ablation, and incomplete ablation was defined as the presence of residual tumor at the ablation site in the 1-month CT scan. The treatment protocol and the collection of data were approved by the Institutional Review Board of our institution. The initial 100 consecutive patients with liver tumors treated with RFA in our institution over a period of 20 months were the subjects of this study. Two other patients who had RFA for hemostasis of ruptured hepatocellular carcinoma (HCC) during emergency laparotomy for hemoperitoneum were excluded from this study. The 100 patients were divided into 2 groups: group I consisted of the first 50 patients, and group II consisted of the more recent 50 patients. The clinical data and treatment outcomes of the 2 groups were compared. The main outcome measures were morbidity, hospital mortality, and complete ablation rate.
Statistical Analysis
Continuous data were expressed as median and range. Comparison between groups was performed using 2 test with Yates correction (or Fisher exact test where appropriate) for nominal variables and Mann-Whitney U test for continuous variables. Independent factors influencing the morbidity rate and complete ablation rate were identified by binary logistic regression analyses. All statistical analyses were performed using the SPSS 10.0 for windows statistical package (SPSS Inc., Chicago, IL). A P value of Ͻ 0.05 was considered to be statistically significant. Table 1 shows the clinical characteristics of the 2 groups. The most common indication for RFA in both groups was HCC (38 patients in group I and 46 patients in group II). Colorectal metastasis was the most common type of liver secondaries treated (8 patients in group I and 3 patients in group II). Other types of liver secondaries included metastases from pancreatic carcinoma (2 patients in group I), nasopharyngeal carcinoma (1 patient in group I), and gastrointestinal stromal tumor (1 patient in group II). The majority of patients in both groups had underlying cirrhosis in association with HCC. The Child's classification of the cirrhotic patients was similar between group I (32 Child's A, 4 Child's B, and 1 Child's C) and group II (38 Child's A, 5 Child's B, and 1 Child's C) (P ϭ 0.517). A similar proportion of patients in both groups (44% and 38%, respectively; P ϭ 0.542) had previous hepatic resection, and RFA was employed to treat intrahepatic tumor recurrences. The proportion of patients who had previous transarterial chemoembolization was also similar between the 2 groups (26% and 20%, respectively; P ϭ 0.476). These patients had HCCs that either failed to respond or regrew in size after previous response to chemoembolization. Liver function parameters and the frequency of comorbid illnesses were comparable between the 2 groups. The majority of patients had solitary tumors in both groups (60% and 70%, respectively). The distribution of tumor size was similar. The median size of the largest tumor was 2.8 cm in both groups (P ϭ 0.508). The range of tumor size was 0.8 -8 cm in group I and 1-6.5 cm in group II, respectively. The distribution of the approaches of RFA was also comparable between the 2 groups. Table 2 shows the treatment results. The total duration of ablation was significantly shorter in group II than in group I (P ϭ 0.037). Among those patients who underwent surgical ablation, there was a significantly reduced operation time in group II compared with group I (P Ͻ 0.001). Hospital stay was also shorter in group II than in group I (P ϭ 0.048). Eight patients in group I suffered from post-RFA morbidity. Two elderly patients, 1 with a preexisting history of atrial fibrillation, developed supraventricular tachycardia after open RFA of liver tumors at segment II and segment VIII, respectively. One patient developed right pleural effusion after open RFA of a segment VIII HCC of 8 cm in diameter. One patient had right basal pneumonia after ablation of tumors in segment VII and segment VIII. Wound infection occurred in 1 patient after open RFA. A patient with previous Whipple operation for pancreatic carcinoma suffered from liver abscess after percutaneous ablation of liver metastasis. Another patient developed sepsis of uncertain origin with positive blood culture of Staphylococcus aureus. Finally, a patient with underlying cirrhosis and previous hepatectomy developed acute respiratory failure, renal failure, liver failure, and shock rapidly on the first day after open RFA of 4 recurrent HCCs of size 4.9 cm, 2.5 cm, 1.0 cm, and 0.6 cm, respectively. The patient subsequently died on the fourth day after RFA. In addition to the aforementioned posttreatment complications, 2 patients in group I had transient hemoglobinuria detected during open ablation of 2 large tumors (8.0 cm and 4.5 cm, respectively) situated close to the right hepatic vein, but this did not result in any clinically significant morbidity after appropriate management with intravenous fluid administration and alkalization of the urine. Two posttreatment complications, 1 pleural effusion, and 1 bile duct injury, were observed in group II. The bile duct injury occurred after open RFA of a 4-cm HCC at segment VI. The patient had jaundice after the procedure and cholangiogram revealed a stricture of segment VI duct. Overall, the treatment morbidity rate was reduced from 16% in group I to 4% in group II (P ϭ 0.046). There was 1 hospital mortality in group I, as mentioned above, and none in group II.
RESULTS
Overall, complete tumor ablation was observed in 92 of the 99 patients (92.9%) who had the postablation CT scan assessment. Seven patients in group I had incomplete ablation, 6 after percutaneous RFA, and 1 after open RFA. Among these 7 patients, 5 had residual tumor at the deep margin. The complete ablation rate in group II was 100%, which was significantly higher than that of 85.7% in group I (P ϭ 0.006). Univariate analysis was performed to evaluate the effect of 14 factors that may potentially influence the treatment morbidity rate. The following factors did not significantly affect the morbidity rate: patient age (Յ65 versus Ͼ65 years; P ϭ 0.722), sex (male versus female; P ϭ 0.708), underlying cirrhosis (no versus yes; P ϭ 0.605), platelet count (Յ100 versus Ͼ100 ϫ 10 9 /L; P ϭ 0.291), serum albumin (Յ35 versus Ͼ 35 g/L; P ϭ 0.277), comorbid illness (no versus yes; P ϭ 0.741), tumor pathology (primary versus metastasis; P ϭ 0.643), size of the largest tumor (Յ3 versus Ͼ3 cm; P ϭ 0.410), type of RFA probe used (single versus clustered; P ϭ 0.714), and duration of ablation (Յ20 versus Ͼ20 minutes; P ϭ 0.192). Serum bilirubin level, number of tumors ablated, approach of ablation and treatment period were significantly associated with morbidity in the univariate analysis (Table 3 ). In a binary logistic regression analysis, hyperbilirubinemia (odds ratio [OR] 10.482; 95% confidence interval [CI] 2.020 -48.628; P ϭ 0.004) and treatment group (OR 10.12; 95% CI 1.530 -65.242; P ϭ 0.012) were the 2 independent factors associated with treatment morbidity.
Univariate analysis of 8 factors that may influence the complete ablation rate was performed. The following factors did not significantly affect the complete ablation rate: tumor pathology (primary versus metastasis, P ϭ 0.286), previous chemoembolization (no versus yes, P ϭ 0.662), tumor number (solitary versus multiple, P ϭ 1.000), size of the largest tumor (Յ3 versus Ͼ3 cm, P ϭ 0.252), type of RFA probe used (single versus clustered, P ϭ 0.412), and total duration of ablation (Յ20 versus Ͼ20 minutes, P ϭ 0.227). In addition to treatment period, the treatment approach was another significant factor affecting the complete ablation rate (Table  4 ). In a binary logistic regression analysis of the 8 factors, treatment period (OR 0.115; 95% CI 0.011-0.854; P ϭ 0.002) and the approach of RFA (OR 9.612; 95% CI 1.048 -47.564; P ϭ 0.014) were 2 independent factors affecting the complete ablation rate.
DISCUSSION
This is the first study that examines the influence of operator experience on the treatment outcomes of RFA for liver tumors. A learning curve effect has been reported in another application of RFA, namely, ablation of accessory cardiac pathway causing tachyarrythmias. 18, 19 A prospective analysis of our initial 100 patients with liver tumors treated by RFA revealed significant improvement in hospital stay, morbidity rate, and complete ablation rate in the second 50 patients compared with the first 50 patients. Our study suggests that a learning curve exists in RFA for liver tumors.
The early reports of the efficacy and safety of RFA for liver tumors in the late 1990s have encouraged rapid spreading of this technique for the treatment of unresectable or even resectable tumors. Because of its perceived technical simplicity and safety, especially in contrast to hepatic resection, many centers including those with less experience in management of liver cancers are embarking on this treatment. Previous reports have not emphasized the importance of operator experience in RFA for liver tumors, so more attention is often paid to the efficacy of the RFA probes than to the training and experience of the clinicians undertaking this treatment. The results of this study serve to emphasize the importance of operator experience in this treatment. We have confined the treatment to a single team of experienced liver 
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Learning Curve in RFA of Liver Tumors surgeons and interventional radiologists in the hope of achieving the best results. Notwithstanding, this study demonstrated that there was still a significant learning curve. Table 5 summarizes the lessons learned from our first 50 cases of RFA for liver tumors. The morbidity rate of 16% in the first 50 patients was relatively high compared with the reported morbidity rate of 0% to 10% in the early studies of RFA for liver tumors. [1] [2] [3] [4] [5] [6] This may in part reflect the prospective documentation of all complications in this study. The morbidity rate of RFA for liver tumors probably has been underestimated in the early studies as some authors might have ignored minor complications. 11 More recent studies have reported a high complication rate of 13% to 20%. 20 -22 The reduction in the morbidity rate in the second 50 patients was at least partly attributable to lessons learned from the complications in the first 50 patients. One patient in group I died of multiorgan failure on the fourth day after open RFA of 4 recurrent HCC tumors, with the largest tumor measuring 4.9 cm. The post-RFA clinical picture of this patient was akin to the multiorgan failure syndrome observed after cryoablation of large liver tumors, which was thought to be related to a systemic cytokine response. 23 The systemic inflammatory response after RFA has been shown to be milder compared with cryotherapy, 24 and multiorgan failure was rarely reported after RFA of liver tumors. 11 Nonetheless, our experience with that patient suggested that multiorgan failure is a possible complication after a large volume hepatic ablation with RFA. We have been more cautious in selecting patients with large tumor volume for RFA since the death of that patient. More consideration has been given to the total volume of liver ablation in patients with multiple tumors, and we now refrain from offering RFA to patients who have Ͼ 3 tumor nodules with 1 or more tumor Ͼ 3 cm. We are conducting an animal study to clarify the systemic inflammatory response to RFA of the liver in relation to the volume of ablation. Another serious complication, liver abscess, occurred in a patient with liver metastasis from pancreatic carcinoma after previous Whipple operation. Retrograde enteric bacterial contamination of the biliary tract from bilioenteric anastomosis is likely to have contributed to the formation of the liver abscess. Bilioenteric anastomoses are known to increase the risk of liver abscess formation after other local treatments of liver tumors such as transarterial chemoembolization and ethanol injection. 25 Since the occurrence of that complication, we have considered the presence of bilioenteric anastomosis a relative contraindication to RFA of liver tumors. Two patients developed cardiac arrhythmia after open RFA in group I. A recent literature review also suggested that cardiac arrhythmia during or after either percutaneous or open RFA of liver tumors were not uncommon. 11 We are now more cautious in obtaining pretreatment consultation with the cardiologist to optimize antiarrhythmic treatment of patients with known cardiac problems and close attention to cardiac monitoring in all patients undergoing RFA. Two patients in group I were noticed to have transient hemoglobinuria, confirmed by free hemoglobin analysis in the urine, during open ablation of large tumors close to the major hepatic veins. This is a complication not mentioned in the previous literature, 11 although a hemolytic effect of RFA has been well described in an animal study. 26 As this is a potentially serious complication that could result in renal failure, we have ensured copious intravenous fluid replacement during ablation of large tumors close to the major intrahepatic veins. With a better experience in case selection and peri-RFA management, the morbidity rate has been reduced to 4% in the second 50 patients. The impact of operator experience on the morbidity rate was confirmed by a multivariate analysis, which showed that the treatment period was an independent factor influencing morbidity.
Another significant improvement that has been observed is a higher complete ablation rate. This is the result of lessons learned in the technical aspects of RFA (Table 5 ). Adequate coverage of the tumor by RFA requires good knowledge of the characteristics of the ablation field created by the probe, especially when overlapping fields are used in multiple ablations to treat a large tumor. The field created by a single or clustered cool-tip probe, in contrast to the systems with multiple retractable curved electrodes, is more cylindrical than spherical. Careful planning of the site and angle of ablation is required to achieve the desired ablation of tumors with adequate margin. This is particularly important in RFA because of the poor visualization of the ablation process due to "microbubbles." 7 Accurate placement of the needle probe in the desired position within the tumor before starting the ablation process is critical in ensuring complete ablation. In the case of percutaneous RFA, patients' respiratory movement can interfere with needle placement. In the early period, we routinely gave sedation before RFA needle insertion for fear of intolerance of the patients to the puncture. However, the patients could not cooperate by holding breath after sedation. We subsequently found that the needle puncture was well tolerated by most patients with local anesthesia alone, while the ablation process tended to induce more pain. By withholding sedation until after needle puncture, precise needle placement within the tumor was enhanced by the patient's cooperation in holding breath. We performed percutaneous RFA for small tumors only and the relatively short duration of ablation was usually well-tolerated by the patients.
The volume of ablation also depends on other factors such as the ablation duration. 27 In our early practice, we followed strictly the recommendation of the manufacturer of the RFA system in setting each ablation cycle to 12 minutes. We observed that the size of the ablated lesion in the postablation CT scan was often greater than that required for a 1-cm margin. We also observed during open ablation that the maximal increase in the volume of ablation occurred in the first 6 -8 minutes, with less increase in the ablation volume afterward. This was confirmed by a subsequent study in a porcine model using the same RFA system. 28 We became flexible in the duration of each ablation cycle in the latter period, using a shorter ablation cycle for a smaller tumor or when there was a concern of injury to nearby structures such as the bile duct. This explains the shorter total ablation time in group II. The shorter operation time among those who underwent surgical ablation in group II was the result of a combination of shorter time needed for planning the needle insertion with experience and shorter ablation duration. Despite the shorter ablation and operation time in group II compared with group I, a better complete ablation rate was achieved.
Our experience in the first 50 cases revealed that the deep margin was the most common site of incomplete ablation. This might be in part due to the difficulty in visualizing the deep margin during ablation, but we suspected that the ablation field beyond the tip of electrode might be more limited than what we initially expected. Unfortunately, there was a paucity of data in the literature regarding the biophysical characteristics of the probe when we started the treatment. We then performed a study in a porcine model and confirmed that the deep margin of the ablations using the cool-tip system extended only 0.5 cm beyond the tip of electrode regardless of various exposure lengths of electrode, ablation duration, and the probe design (single or clustered); whereas the ablation field extended for 1.5 cm laterally even with the single electrode. 28 As a result, we have positioned the tip of the probe deeper at the tumor edge to ensure adequate deep margin in the more recent cases.
Of the 7 cases of incomplete ablation in group I, 6 were performed percutaneously. For percutaneous RFA, a single electrode is better tolerated than a clustered electrode and is usually adequate for small tumors Ͻ 3 cm. However, depending on the exact size and shape of the tumor, 2 or more ablations with the single electrode may be needed to achieve adequate margin. In our early experience, we used 1 electrode to ablate the deep part of the tumor and then reposition the same probe for the second ablation when 2 ablations were required. However, we found accurate placement of the electrode for the second ablation difficult because the border of the tumor was obscured by "microbubbles" once the RFA was started. As a result, we modified our technique of percutaneous RFA in the more recent cases for those patients requiring more than 1 ablation. Instead of using a single probe to ablate 1 part of the tumor after another, 2 probes were placed side by side in the desired positions before starting the RFA. The 2 electrodes were then connected in turn to the RFA generator for the ablation. This "doubleelectrode" technique allows more accurate ablation of the tumor and is another factor that has contributed to the improved complete ablation rate.
This study illustrates that operator experience plays an important role in determining whether complete ablation of liver tumors can be achieved. The close collaboration between the surgeons and radiologists in our team approach in the development of this treatment has helped the process of learning the best strategy of ablation. After the first 50 cases of RFA with a complete ablation rate of 85.7%, the complete ablation rate has improved to 100% in the more recent 50 patients. This is among the best complete ablation rates that have been reported in the literature. 7, 29 The impact of operator experience on the completeness of ablation was also confirmed by a multivariate analysis that identified the treatment period as a significant influencing factor. Besides, in accordance with a similar finding of another group, 21 surgical ablation was also associated with a better complete ablation rate than percutaneous ablation. Intraoperative ultrasound may provide better visualization of the tumor and thus allows a more accurate placement of the probe. This is further enhanced by the freedom of the probe insertion at different angles in the open or laparoscopic approaches, with mobili-Annals of Surgery • Volume 239, Number 4, April 2004 Learning Curve in RFA of Liver Tumors zation of the liver if necessary. However, with the aforementioned modifications in the technique of ablation, complete ablation was achieved in all the 19 cases of percutaneous RFA in group II. The identification of a learning curve in RFA for liver tumors has an important implication for centers preparing to start this new treatment. RFA for liver tumors should not be viewed as a simple technique but rather a specialized treatment modality that should be undertaken only by clinicians with adequate knowledge and experience in interventional therapies for liver tumors. Furthermore, appropriate training may aid clinicians in mastering the technique. There are several measures that may help clinicians to overcome the learning curve faster. When initiating the treatment, a team approach with close collaboration between surgeons and interventional radiologists may shorten the learning curve. Learning the experience of others by appraisal of the literature and visiting centers specialized in this treatment may also help. Similar to the case of laparoscopic surgery, practice in animal models and organization of training workshops may allow clinicians to learn the skills of ultrasonic localization of liver tumors, placement of RFA probes, and monitoring of the ablation process. A group of investigators has developed an in vivo tumor-mimic model by injecting an agarose-based mixture into porcine livers to create sonographic targets for learning ultrasound-guided RFA. 30 In addition to serving the purpose of training, animal models in laboratory studies are also helpful in resolving problems encountered in the clinical application of RFA, as exemplified by our experience. This is particularly pertinent because RFA treatment has been introduced into clinical practice with limited data of basic research in animal studies. 31, 32 The continuous evolution of the RFA probes and the development of new treatment strategies such as combination of RFA with transarterial chemoembolization 33 may further extend the learning curve in RFA for liver cancers. While overcoming the learning curve, it is the clinicians' obligation to audit their own performance to evaluate if the treatment results are improved with accumulated experience.
The effect of a learning curve needs to be borne in mind when interpreting data of RFA for liver tumors in the literature. Currently, many centers are reporting their initial experience with RFA for liver tumors. Even in the recently published reports, many studies had fewer than 50 patients. 22,34 -37 The possible effect of a learning curve on the results of these studies should be taken into consideration in the appraisal of the data. A few recent studies with 100 patients or more from specialized centers reported favorable results in terms of morbidity, mortality, and complete ablation rates. 21,38 -40 The accumulated experience in these centers have certainly contributed to the good results.
In conclusion, this study demonstrated that there is a learning curve in RFA for liver tumors, which involves the accumulation of experience in patient selection, selection of the appropriate approach, technique of placement of electrodes and ablation, and provision of the optimum peri-RFA management. Clinicians embarking on this treatment should recognize and overcome this learning curve before they can provide the optimum treatment to the patients. With adequate experience, RFA can be used to ablate liver tumors with low morbidity, low mortality, and a high complete ablation rate.
